Microparticles and cancer thrombosis in animal models

• Few data are available about the implication of MPs in cancer associated-VTE through animal model of cancer.
• Ectopic, orthotopic tumor induction and experimental metastasis are the main cancer animal models, and pancreatic cancer is the most represented.
• Tumor cell-derived MPs can promote thrombus formation in TF-dependent manner.
• Antiplatelet or anticoagulant treatment may prevent tumor progression and the formation of metastases in addition of coagulopathy

ABSTRACTCancer-associated venous thromboembolism (VTE) constitutes the second cause of death after cancer. Many risk factors for cancer-associated VTE have been identified, among them soluble tissue factor and microparticles (MPs). Few data are available about the implication of MPs in cancer associated-VTE through animal model of cancer.The objective of the present review was to report the state of the current literature about MPs and cancer-associated VTE in animal model of cancer.Fourteen series have reported the role of MPs in cancer-associated VTE, through three main mouse models: ectopic or orthotopic tumor induction, experimental metastasis by intravenous injection of tumor cells into the lateral tail vein of the mouse. Pancreatic cancer is the most used animal model, due to its high rate of cancer-associated VTE. All the series reported that tumor cell-derived MPs can promote thrombus formation in TF-dependent manner. Some authors reported also the implication of phosphatidylserine and PSGL1 in the generation of thrombin. Moreover, MPs seem to be implicated in cancer progression through a coagulation-dependent mechanism secondary to thrombocytosis, or a mechanism implicating the regulation of the immune response. For these reasons, few authors have reported that antiplatelet and anticoagulant treatments may prevent tumor progression and the formation of metastases in addition of coagulopathy.